Table 2 HIV-1-RNA suppression by ultra-LA dolutegravir

From: Ultra-long-acting removable drug delivery system for HIV treatment and prevention

Mouse

hCD45(%)

hCD4 (%)

Nadir (HIV-RNA copies/ml plasma)

Duration of suppression below LOQ in CVS (days)

S1

37.9

76.1

LOQ

54

S2

60.3

77.5

14,746.3

27

S3

43.6

71.5

38,282.0

16

S4

53

75.6

30,863.0

41

Mean

48.7

75.2

21,022

33.5

SD

9.9

2.56

17,000

15.0

  1. BLT mice with indicated amount of human CD45+ (hCD45) cells and human CD3+CD4+ (hCD4) in peripheral blood were intravenously infected with HIV-1JRC-SF and treated with ultra-LA dolutegravir formulation (250 mg/kg) 3 weeks later. Limit of quantitation (LOQ) was 1375 copies/ml in plasma and 81 copies/60 µl in CVS
  2. CVS cervico-vaginal lavage, SD standard deviation
Back to article page